Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021.
ENPNewswire-November 3, 2021--Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
(C)2021 ENPublishing - http://www.enpublishing.co.uk
Release date- 02112021 - PRINCETON, N.J. - Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced multiple scientific presentations at the American Academy of Optometry (AAOpt) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.
'The American Academy of Optometry annual meeting is the largest meeting in optometry and works to provide exceptional education, support innovative research, and disseminate knowledge to advance optometric practice and improve patient care,' said Marian Macsai, MD Chief Medical Officer of Oyster Point Pharma. 'We are pleased to share a number of data presentations from company-sponsored clinical trials at this year's meeting highlighting the recently approved TYRVAYAO (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.'
Papers/Posters
Title: Effect of OC-01 (varenicline solution) Nasal Spray Compared to Vehicle Control on Dry Eye Disease Sign Outcomes by Baseline Subgroup Characteristics
Presenter: Leslie O'Dell, OD
Date/Time: Thursday, November 4th, 4:30 - 6:30pm ET
Title: OC-01 (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease in Subjects with Mild, Moderate, and Severe Dry Eye Disease as Determined by Baseline Eye Dryness Score: ONSET-1 and ONSET-2 Trial Outcomes
Presenter: Paul Karpecki, OD
Date/Time: Thursday, November 4th, 4:30 - 6:30pm ET
Title: Safety Assessment of OC-01 (varenicline) Nasal Spray in Subjects with Dry Eye Disease
Presenter: Walter O. Whitley, OD
Date/Time: Thursday, November 4th, 4:30 - 6:30pm ET
About Dry Eye Disease and the Role of Tear Film
Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence1,2. It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes...
To continue reading
Request your trial